Amends the Social Security Act to adjust the rules for engineered cyclic peptides under the Drug Price Negotiation Program.
The Next Generation Medicines Act of 2026 amends the Social Security Act to modify the criteria for engineered cyclic peptides under the Drug Price Negotiation Program. It extends the qualifying period for these peptides from 7 to 11 years and defines engineered cyclic peptides as polymers composed of amino acids with specific structural characteristics. The changes apply to lists published on or after the enactment date of the bill.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.